Source - SMW
Caner and neurological-condition focused Evgen Pharma said a trial of a treatment for subarachnoid haemorrhage, a type of stroke, had failed to achieve its primary goal.

The primary aim of the trial, to reduce blood flow velocity in the middle cerebral artery was, not achieved, with no significant difference between the treatment -- called SFX-01 -- and placebo arms.  

SFX-01 was, however, shown to be well-tolerated with no safety concerns.

In March, Evgen Pharma reported positive data from a trial using  SFX-01 for the treatment of metastatic breast cancer.

'Evgen remains well funded and will concentrate its efforts on future partnering whilst developing product formulation for use in STEM II and other investigator-led clinical studies,' it said.

Chief executive Steve Franklin said the company was 'surprised and disappointed' by the latest study findings.

'In March, we reported that SFX-01 had demonstrated positive efficacy and safety data in our STEM trial for metastatic breast cancer, so it is naturally disappointing not to have followed this with another positive result,' he added.

The company later clarified on Monday that it remained well funded to pursue commercial opportunities for SFX-01 in oncology and other disease areas.

'Evgen is unlikely to pursue the subarachnoid haemorrhage opportunity given the data announced earlier today,' it said.

'The reference to a strategic review relates to the significance of these data on related neurological indications.'  


At 2:58pm: (LON:EVG) Evgen Pharma Plc share price was -7.95p at 8.05p



Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.